Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells

Masaki Honda1, Jumpei Kiyokawa, Mitsuyasu Tabo

  • 1Safety Assessment Department, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. hondamsk@chugai-pharm.co.jp

Insights

Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) accurately predict drug responses. Patch-clamp assays using hiPS-CMs show promise for assessing drug-induced cardiotoxicity and arrhythmia risk in clinical settings.

Area of Science:

  • Biomedical Engineering
  • Stem Cell Biology
  • Cardiovascular Pharmacology

Background:

  • Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are valuable for in vitro cardiotoxicity assessment.
  • Understanding their electrophysiological properties is crucial for predicting drug effects, including QT prolongation.

Purpose of the Study:

  • To characterize the electrophysiological and pharmacological properties of hiPS-CMs.
  • To validate hiPS-CMs as a model for predicting human cardiac drug responses.

Main Methods:

  • hiPS cells were differentiated into cardiomyocytes using the embryoid body method.
  • RT-PCR was used to detect cardiac ion channel gene expression.
  • Whole-cell patch-clamp recordings were performed on single hiPS-CMs.

Main Results:

  • Major cardiac ion currents (I(Na), I(Ca), I(Kr), I(Ks)) showed voltage-dependence.
  • Ion channel blockers affected action potential duration (APD) as expected (prolonged by I(Kr)/hERG and I(Ks) blockers, shortened by I(Ca) blocker).
  • Pharmacological responses to terfenadine and verapamil mirrored clinical observations.

Conclusions:

  • Patch-clamp assays with hiPS-CMs can accurately predict human cardiac responses to drug candidates.
  • This method is a promising electrophysiological assay for assessing drug-induced arrhythmia risk.